| Literature DB >> 36234598 |
Zayakhuu Gerelkhuu1,2, Yong-Ill Lee3,4, Tae Hyun Yoon1,2,5.
Abstract
In recent decades, upconversion nanomaterials (UCNMs) have attracted considerable research interest because of their unique optical properties, such as large anti-Stokes shifts, sharp emissions, non-photobleaching, and long lifetime. These unique properties make them ideal candidates for unified applications in biomedical fields, including drug delivery, bioimaging, biosensing, and photodynamic therapy for specific cancers. This review describes the general mechanisms of upconversion, synthesis methods, and potential applications in biology and their biological responses. Additionally, the biological toxicity of UCNMs is explained and summarized with the associated intracellular association mechanisms. Finally, the prospects and future challenges of UCNMs at the clinical level in biological applications are described, along with a summary of opportunity for biological as well as clinical applications of UCNMs.Entities:
Keywords: bioimaging; biological response; biosensor; lanthanide-based nanomaterials; upconversion nanomaterials
Year: 2022 PMID: 36234598 PMCID: PMC9565472 DOI: 10.3390/nano12193470
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.719
Figure 1Overview of upconversion mechanisms.
Figure 2Various properties of upconversion nanomaterials and biological applications.
Cytotoxicity of upconversion nanomaterials in vitro.
| Nanoparticles | Size (nm) | Shape | Surface Ligand | Cell Viability | Cell | Conc. | Ref. |
|---|---|---|---|---|---|---|---|
| NaYF4:Yb3+/Er3+ | 50 | Hexagonal | SiO2 | n/a | In vivo: mice | n/a | [ |
| NaYF4:Yb3+/Tm3+ | n/a | n/a | TiO2 | n/a | HepG2-CCK-8 assay | n/a | [ |
| NaGdF4/GdF3:Yb3+,Er3+ | 30 | Hexagonal | PEG | 90% | HeLa, MCF-7, A549 | 62.5, 125, 250, 500 μg/mL | [ |
| NaGdF4/GdF3:Yb3+,Er3+ | 30 | Hexagonal | OA | 63% | HeLa, MCF-7, A549 | 62.5, 125, 250, 500 μg/mL | [ |
| LiLuF4:Yb,Er@nLiGdF | 8.5 (core) | n/a | mSiO2 | 92.3% | MCF-7 | 50, 100, 200, 400, 800 μg/mL | [ |
| NaYF4:Yb3+/Er3+ | 47 ± 1 | Hexagonal | Thin SiO2 | 51 ± 5%, 110 ± 12& | RAW 264.7 | 12.5 and 200 μg/mL | [ |
| NaY0.78Yb0.2Er0.02F4 | 93 ± 8 | Hexagonal | PEI | 63% | murine bone marrow mesenchymal stem | 1–25 μg/mL during 1–2 days | [ |
| NaYF4:Yb,Er@NaYF4:Nd@NaYF4 | 35 | Irregular | Fe(OH)3 | [ | |||
| Y2O3:Er3+/Yb3+ | 70 ± 10 | n/a | Folic acid | >80% | HeLa, MDA-MD-231, MCF-7 | 1 μg/mL | [ |
| NaYF4:Yb3+,Er3+ | 22 ± 1 | Hexagonal | AMPA | >80% | CHO-K1 | Low 10 μg/mL | [ |
| NaLuGdF4:Yb3+/Er3+ (Tm3+) | ~80 | n/a | Malonic acid | >80% | HeLa cell | 0–600 μg/mL | [ |
| NaGdF4:Yb3+, Er3+ | 3.5 ± 0.4 | Hexagonal | NOBF4 | IC50 = 0.81 ± 0.06 μg/mL | RAW 264.7 | 0.1–50 μg/mL | [ |
| NaYF4:Yb3+,Er3+ | 19.9 ± 1.1 | Hexagonal | Citrate | >80% | Human HaCaT keratinocyte cells | 12.5–200 μg/mL | [ |
| NaYF4:Yb3+,Er3+ | 26.1 ± 1.9 | Hexagonal | Cucurbit[n]urils (CB[n]) | >50% | RAW 264.7 | 50 μg/mL | [ |
Abbreviations: AMPA, (aminomethyl)phosphonic; APTES, 3-aminopropyl)triethoxysilane; DHCA, 3,4-dihydrocinnamic acid; MAEP, poly(monoacryloxyethyl phosphate; AA, alendronate, EDTMP, ethylenediamine tetra(methylene phosphonate); PMAO, poly(maleic anhydride-alt-1-octadecene).
Figure 3Cellular uptake and intracellular mechanism of upconversion nanomaterials.